Clinical Trials in Córdoba, Spain

5 recruiting

Showing 119 of 19 trials

Recruiting
Phase 2

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Breast CancerBreast Neoplasms
Merck Sharp & Dohme LLC372 enrolled17 locationsNCT06797635
Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled257 locationsNCT06312176
Recruiting
Phase 3

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 2

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Breast Cancer
MedSIR976 enrolled41 locationsNCT05708235
Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 1Phase 2

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 3

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626
Recruiting
Phase 2

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
Phase 3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Gilead Sciences1,514 enrolled288 locationsNCT05633654
Recruiting
Phase 1

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd90 enrolled13 locationsNCT06458712
Recruiting
Phase 3

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
Phase 2

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

HER2-positive Breast Cancer
MedSIR165 enrolled36 locationsNCT06172127
Recruiting
Phase 3

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

Invasive Breast Cancer Early Stages
Spanish Breast Cancer Research Group8,000 enrolled73 locationsNCT03390894
Recruiting
Not Applicable

Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments

Cancer, Breast
Universidad de Córdoba123 enrolled2 locationsNCT05289258
Recruiting
Not Applicable

Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)

CardiotoxicityCancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)Elderly+1 more
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León514 enrolled14 locationsNCT03711110
Recruiting

A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

Breast Neoplasms
Spanish Breast Cancer Research Group1,867 enrolled40 locationsNCT02819882
Recruiting
Phase 3

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

CarcinomaNon-Small-Cell Lung
AstraZeneca324 enrolled283 locationsNCT05261399
Recruiting
Not Applicable

A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection

Women's Health: Neoplasm of Breast
Umbria Bioengineering Technologies10,000 enrolled9 locationsNCT06291896